Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma
- 182 Downloads
This study was supported in part by research funding from grants “Red Temática de Investigación Cooperativa en Cancer” (RD06/0020/0031 and RD06/0020/0005) and “Red de Biobancos Hospitalarios” (RD09/0076/00021), research project from the “Instituto de Salud Carlos III” (PS09/01882), research grants from the “Instituto de Salud Carlos III” (CA08/00141, CM10/00321 and CM09/00038), and grant from “Ministerio de Ciencia e Innovación” (BES2008-008053).
Compliance with ethical standards
This study was approved by institutional ethical committee. The written informed consent from all patients included in both studies was obtained according to the Declaration of Helsinki. The study was performed in accordance with the ethical principles of the Declaration of Helsinki and in compliance with institutional or national laws.
Conflict of interest
Adrían Alegre has served on advisory boards for Janssen, Celgene, Amgen, and Takeda and received research support from Janssen, Celgene, and Amgen. Javier de la Rubia has received a speaker honorarium from Abbvie, AMGEN, Celgene, Janssen, and Takeda. The other authors, Margarita Blanes, José Ignacio Lorenzo, Paz Ribas, Ana Jiménez, José David González, Ma. José Cejalvo and Carlos Solano, declare they have no conflict of interest.
- 1.Blanes M, de la Rubia J, Lahuerta JJ, González JD, Ribas P, Solano C, Alegre A, Sanz MA (2009) Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. Leuk Lymphoma 50:216–222CrossRefPubMedGoogle Scholar
- 2.Lahuerta JJ, Martínez-López J, Grande C et al (2000) Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in multiple myeloma. Br J Haematol 109:138–147CrossRefPubMedGoogle Scholar
- 5.Blanes M, Lahuerta JJ, González JD, Ribas P, Solano C, Alegre A, Bladé J, San Miguel JF, Sanz MA, de la Rubia J (2013) Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol Blood Marrow Transplant 19:69–74CrossRefPubMedGoogle Scholar
- 6.Lahuerta JJ, Mateos MV, Martínez-López J et al (2010) Grupo Español de MM y Programa para el Estudio de la Terapéutica en Hemopatía Maligna Cooperative Study Groups. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematol. 95:1913–1920CrossRefGoogle Scholar
- 7.Jung SH, Lee JJ, Kim JS, Min CK, Kim K, Choi Y, Eom HS, Joo YD, Kim SH, Kwak JY, Kang HJ, Lee JH, Lee HS, Mun YC, Moon JH, Sohn SK, Park SK, Park Y, Shin HJ, Yoon SS, Korean Multiple Myeloma Working Party (2018) Korean Multiple Myeloma Working Party. Phase 2 study of an intravenous busulfan and melphalan conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma (KMM150). Biol Blood Marrow Transplant 24:923–929CrossRefPubMedGoogle Scholar
- 8.Blanes M, González JD, Lahuerta JJ, Ribas P, Lorenzo I, Boluda B, Sanz MA, de la Rubia J (2015) Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma. Leuk Lymphoma 56:415–419CrossRefPubMedGoogle Scholar
- 9.Rosiñol L, Oriol A, Ríos R, et al. Bortezomib, lenalidomide, and dexamethasone (VRD-GEM) as induction therapy prior to autologous stem cell transplantation (ASCT) in multiple myeloma: results of a phase III PETHEMA/GEM trial. 44th Annual meeting of the European Society for Blood and Marrow Transplantation, 2018, S003Google Scholar